Specification Sheet

Guardant360^® CDx provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing.

Lung Cancer Brochure

Test patients newly diagnosed with NSCLC with Guardant360^® to help accelerate time to complete biomarker results

Patient Brochure

Find treatment options with the ease of a blood draw

Educational Booklet

You have questions. A simple blood test may have answers.

Clinical cancer research

Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer

Clinical lung cancer

Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Journal of Clinical Oncology

Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

Jama Oncology

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer